Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
NEW YORK, Nov. 18, 2019 — Hoth Therapeutics, Inc. (NASDAQ: HOTH) (“HOTH” or the “Company”), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, […]
TORONTO, Nov. 13, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or the “Company“) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today that the license of its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”) under the […]
PHARMA GRADE PROCESS COULD REDUCE THE PRODUCTION TIME FOR TARGETED CANNABINOID MOLECULE(S) FSD Pharma Inc. (“FSD Pharma”)(OTC: FSDDF) and Solarvest BioEnergy Inc. (SVS) (“Solarvest”) ()Parties”), a technology company which has developed an algal-based flexible production platform […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
